The shares of Amneal Pharmaceuticals, Inc. (NYSE:AMRX) has been pegged with a rating of Mkt Perform by SVB Leerink in its latest research note that was published on March 8th, 2019. The research company has also assigned a $12 price target. SVB Leerink wasn’t the only research firm that published a report of Amneal Pharmaceuticals, Inc., with other equities research analysts also giving their opinion on the stock. Morgan Stanley advised investors in its research note published on December 14th, 2018, to Equal-Weight the AMRX stock. The stock had earned Hold rating from SunTrust when it published its report on October 16th, 2018. The stock was given Outperform rating by RBC Capital Mkts in its report released on August 13th, 2018. Morgan Stanley was of a view that AMRX is Overweight in its latest report on July 23rd, 2018 while giving it a price target of $22. B. Riley FBR, Inc. thinks that AMRX is worth Buy rating. This was contained in the firm’s report on June 22nd, 2018 in which the stock’s price target was also moved to $26.
Amongst the analysts that rated the stock, 0 have recommended investors to sell it, 7 believe it has the potential for further growth, thus rating it as Hold while 1 advised investors to purchase the stock. The consensus currently stands at a Hold while its average price target is $17.50. The price of the stock the last time has raised by 19.86% from its Week high price while it is raised higher than its 52-Week low price. A look at the stock’s other technical shows that its 14-day RSI now stands at 60.03.
The shares of the company added by 0.65% during the trading session on Thursday, reaching a low of $13.49 while ending the day at $13.94. During the trading session, a total of 2.26 million shares were traded which represents a -119.34% decline from the average session volume which is 1.03M shares. AMRX had ended its last session trading at 13.85. Amneal Pharmaceuticals, Inc. currently has a market cap of $4.30B while its P/E earnings growth sits at 2.59, with a beta of 1.39. Amneal Pharmaceuticals, Inc. debt-to-equity ratio currently stands at 5.33, while its quick ratio hovers at 1.50. AMRX 52-week low price stands at $11.63 while its 52-week high price is $24.48.
The company in its last quarterly report recorded $0.33 earnings per share which is above the $0.27 predicted by most analysts. The Amneal Pharmaceuticals, Inc. generated $497.53 million in revenue during the last quarter, which is slightly higher than the $481.10 million predicted by analysts. In the second quarter last year, the firm recorded $0.28 earnings per share. Compared to the same quarter last year, the firm’s revenue was up by 15.15%. Amneal Pharmaceuticals, Inc. has the potential to record -0.17 EPS for the current fiscal year, according to equities analysts.
Investment analysts at Deutsche Bank published a research note on February 13th, 2019 where it informed investors and clients that Molson Coors Brewing Company (NYSE:TAP) is now rated as Hold. Their price target on the stock stands at $63. Morgan Stanley also rated TAP as Downgrade on December 14th, 2018, with its price target of $44 suggesting that TAP could surge by 11.47% from its current share price. Even though the stock has been trading at $60.59/share, analysts expect it to surge higher by -0.17% to reach $68.33/share. It started the day trading at $60.86 and traded between $60.295 and $60.49 throughout the trading session.
A look at its technical shows that TAP’s 50-day SMA is 62.14 while its 200-day SMA stands at 63.61. The stock has a high of $81.78 for the year while the low is $54.17. The company’s P/E ratio currently sits at 11.73, while the P/B ratio is 0.97. At the moment, only of Molson Coors Brewing Company shares were sold short. The company’s average trading volume currently stands at 1.92M shares, which means that the short-interest ratio is just 4.48 days. Over the past seven days, the company moved, with its shift of 0.75%. Looking further, the stock has dropped -3.28% over the past 90 days while it lost -3.72% over the last six months.
The change in the stock’s fortunes has led to several institutional investors altering their holdings of the stock. The Vanguard Group Inc bought more TAP shares, increasing its portfolio by +3.69% during the last quarter. This move now sees The Vanguard Group Inc purchasing 698,957 shares in the last quarter, thus it now holds 19,644,999 shares of TAP, with a total valuation of $1,211,310,638. Independent Franchise Partners LL meanwhile sold more TAP shares in the recently filed quarter, changing its stake to $537,294,450 worth of shares. Dodge Cox followed the path by increasing its TAP portfolio by +2.97% in the quarter. This means that Dodge Cox bought 248,732 shares in the last quarter and now controls 8,616,173 shares of the TAP stock, with the valuation hitting $531,273,227.
Similarly, SSgA Funds Management Inc increased its Molson Coors Brewing Company shares by +3.19% during the recently filed quarter. After buying 241,335 shares in the last quarter, the firm now controls 7,804,587 shares of Molson Coors Brewing Company which are valued at $481,230,834. In the same vein, JPMorgan Investment Management I decreased its Molson Coors Brewing Company shares by during the most recent reported quarter. The firm sold -1,744,662 shares during the quarter which decreased its stakes to 5,639,441 shares and is now valued at $347,727,932. Following these latest developments, around 0.40% of Molson Coors Brewing Company stocks are owned by institutional investors and hedge funds.